Standard of Care Evolution

Pick the patients for your first pivotal trial

Sleuth maps today’s standard of care line by line, dates every readout that could change it before you launch, and redraws the market for each result, so you know where to start.

Free to try on your own asset

The analysis

The market you’ll launch into, and where your asset should start

What’s the standard today, and the bar in each line?

Each line of therapy and patient group, with its standard regimen, the result to beat, how many patients there are, and how long they stay on treatment.

What could change it before we launch?

Every late-stage trial that could change a standard by your launch year, with its comparator, its eligibility, and a dated readout, including your own next data.

Where should we start if each readout goes either way?

The market redrawn for each result, and the patient groups ranked for your first pivotal trial, with what would change the order.

Describe your asset, and Sleuth maps its launch market

Step 1

Describe your asset

Say what it has shown, the edge you expect, and the decision you face, plus the markets and the year you expect to launch.

Step 2

Decide what counts

Choose how to rank each patient group, such as the result to beat, patient numbers, time to readout, and competition, and how much each one counts.

Step 3

Shape the plan

See the three steps Sleuth will run: map today’s standard of care, find what could change it, and project where your asset should start. Add a trial to watch before it runs.

Step 4

Get the analysis

The patient groups ranked for your first pivotal trial, the readouts that could change the order, and the market map as a dataset.

Where should a CDK2 inhibitor’s first pivotal trial start? After a CDK4/6 inhibitor.

The HR+/HER2-negative breast cancer market of 2031, redrawn for 25 readouts. Second line stays first unless the 2028 class readouts or the drug’s Phase 1b fail.

Standard of Care Evolution: HR+/HER2-negative breast cancer

Standard of Care Evolution: HR+/HER2-negative breast cancer: Start in 2L after a CDK4/6 inhibitor, where approved regimens reach 9.3 – 11.1 months median PFS.
Can I use it for a forecast?

Yes. The map sizes the patients and the time on treatment in each line for your launch year, which is where a forecast starts.

How are readouts dated?

From company guidance or the FDA where there is one, and from the trial registry or other sources where there isn’t. The map marks which is which.

Does it count our own next readout?

Yes. Your next data, such as a Phase 1b, goes on the timeline with every other readout, and the ranking shows where you’d start if it fails.

Which markets does it cover?

The markets you choose. The example maps the U.S.

Does it cover every line of therapy?

Yes. Each line and patient group gets its own standard, benchmark, and patient numbers, including the groups today’s pivotal trials left out.

Map the market your asset will launch into

Set up in Claude, ChatGPT, or Copilot